Search Results
Debate: Optimal approach for the management of CLL patients with del(17p) - Ibrutinib
Debate: Optimal approach for the management of CLL patients with del(17p) - Novel Agents
CLL: Optimal approaches for patients with deletion 17p
Treatment options for the young CLL patient with deletion 17p: Do they need a different approach?
Evaluation 17p del CLL patients treated with ibrutinib: cross-study analysis of treatment outcomes
Debate: Which is the optimal approach for CLL? - FCR
Real-world analysis of the impact of del(17p) on ibrutinib efficacy in CLL
Ibrutinib for CLL with Deletion 17p
Debate: Best Frontline Regimen for a CLL Patient Aged 60 Who Requires Therapy - FCR
Case 2: Choosing Treatment for CLL With Del(17p)
Novel Treatment Options in CLL
CLL: Long-term updates on ibrutinib and idelalisib
